Is Optimal Streptokinase Treatment Possible for Every Patient with Myocardial Infarction?

Philip Hugenholtz; M. L. Simoons; Patrick W. Serruys

doi:10.1007/978-3-642-69720-3_21

Related publications

Article1982

Sequential intracoronary streptokinase and transluminal angioplasty in unstable angina with evolving myocardial infarction

Richard S. Meltzer, Marcel van den Brand, Patrick W. Serruys, P. Fioretti, Paul G. Hugenholtz

American Heart Journal

Letter2020

Considerations for an optimal definition of procedural myocardial infarction

Gregg W. Stone, Ori Ben‐Yehuda, Joseph F. Sabik, A. Pieter Kappetein, Patrick W. Serruys

European Heart Journal

Chapter in a book2012

Acute Myocardial Infarction (MI)

Howard R. Champion, Nova L. Panebianco, Jan J. De Waele, Lewis J. Kaplan, Manu L. N. G. Malbrain, Annie L. Slaughter, Walter L. Biffl, Clay Cothren Burlew, Ernest E. Moore, Parita Bhuva, Barnett R. Nathan, Michael E. Silverman, Richard D. Shih, Luciano Gattinoni, Eleonora Carlesso, Pietro Caironi, Argyris Michalopoulos, Matthew E. Falagas, Angela M. Mills, Anthony J. Dean, Christopher R. Wyatt, Ernest E. Moore, Clay Cothren Burlew, Chadwick D. Miller, Karina M. Soto‐Ruiz, Joseph Varón,

Article2014

A polymorphism in the gene for protein tyrosine phosphatase 1b is associated with altered lipid profile and myocardial infarction

Stephanie Bezzina Wettinger, Carine J.M. Doggen, A.C. Spek, Alex E. Felice, Frits R. Rosendaal, Pieter H. Reitsma

Atherosclerosis

Article1994

31P Optimal intensity of long-term oral anticoagulant therapy in 3404 post-myocardial infarction patients

Aïda J. Azar, Jaap W. Deckers, Frits R. Rosendaal, E. Briët

Controlled Clinical Trials